Meihua Biological released its 2026 interim report, with net profit attributable to the parent company of 662 million yuan, a decrease of 62.56% compared with the same period last year. The company's total operating revenue was 12.235 billion yuan, a slight decrease of 0.37% year-on-year; net cash inflow from operating activities was 389 million yuan, down 83.17% year-on-year. The company's latest gross margin was 12.93%, a decrease of 10.25 percentage points from the same period last year; diluted earnings per share was 0.24 yuan, down 61.29% year-on-year.
MeiHua Holdings Group Co LtdNet profit down 62.56% and operating cash flow down 83.17% in interim report.